Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Insmed Inc (NASDAQ:INSM)

9.60
Delayed Data
As of Jun 24
 -0.68 / -6.61%
Today’s Change
9.40
Today|||52-Week Range
28.66
-47.11%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$594.0M

Company Description

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. The company is focused on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.

Contact Information

Insmed, Inc.
Building 10
Bridgewater New Jersey 08807-3365
P:(908) 977-9900
Investor Relations:
(908) 947-4326

Employees

Shareholders

Mutual fund holders57.22%
Individual stakeholders5.23%
Other institutional35.70%

Top Executives

Will LewisPresident, Chief Executive Officer & Director
Andrew T. DrechslerChief Financial Officer
Walter R. PerkinsChief Technology Officer
Eugene Jeffrey SullivanChief Medical & Scientific Officer
John GollVice President & Corporate Controller